Conclusion
In children treated with Hemangiol® for proliferative IH, this
post-marketing surveillance drug study reported an AE incidence rate of
26.6%, of which 8.5% non-fatal SAEs, supporting the importance of
parental therapeutic education. The pre-therapeutic paediatric
cardiology consultation should not be systematic but only indicated on
selected at-risk patients. In addition to the conventional initiation
protocol with a 3-week titration phase in day care hospital, we suggest
using a rapid initiation protocol with a 48-hours dose escalation in
conventional hospitalization when treatment is urgent.